KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBITDA (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of EBITDA data on record, last reported at -$31.7 million in Q3 2025.

  • For Q3 2025, EBITDA rose 7.78% year-over-year to -$31.7 million; the TTM value through Sep 2025 reached -$17.9 million, down 134.07%, while the annual FY2024 figure was -$25.0 million, 56.85% up from the prior year.
  • EBITDA reached -$31.7 million in Q3 2025 per NKTR's latest filing, up from -$36.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $247.0 million in Q4 2022 and bottomed at -$152.8 million in Q2 2022.
  • Average EBITDA over 5 years is -$20.1 million, with a median of -$44.9 million recorded in 2023.
  • Peak YoY movement for EBITDA: skyrocketed 301.68% in 2021, then plummeted 45.1% in 2024.
  • A 5-year view of EBITDA shows it stood at $223.3 million in 2021, then rose by 10.63% to $247.0 million in 2022, then crashed by 30.31% to $172.2 million in 2023, then tumbled by 45.1% to $94.5 million in 2024, then tumbled by 133.51% to -$31.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$31.7 million in Q3 2025, -$36.2 million in Q2 2025, and -$44.5 million in Q1 2025.